Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
791 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape. Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively. Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology). - The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 7 Chronic Lymphocytic Leukemia (CLL) - Overview 8 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 9 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 35 Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 51 Chronic Lymphocytic Leukemia (CLL) - Drug Profiles 102 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 748 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 756 Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 758 Appendix 770
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017 29 Number of Products under Development by Companies, H1 2017 31 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 32 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 33 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 34 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 35 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 36 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 37 Number of Products under Development by Universities/Institutes, H1 2017 38 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 39 Products under Development by Companies, H1 2017 40 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 41 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 42 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 43 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 44 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 45 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 46 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 47 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 48 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 49 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 50 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 51 Products under Development by Universities/Institutes, H1 2017 52 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 54 Number of Products by Stage and Target, H1 2017 56 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 57 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 58 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 59 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 60 Number of Products by Stage and Mechanism of Action, H1 2017 62 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 63 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 64 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 65 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 66 Number of Products by Stage and Route of Administration, H1 2017 68 Number of Products by Stage and Molecule Type, H1 2017 70 Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2017 71 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2017 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2017 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2017 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics Sarl, H1 2017 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2017 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Alvotech Iceland, H1 2017 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2017 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2017 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptose Biosciences Inc, H1 2017 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H1 2017 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2017 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2017 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2017 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2017 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2017 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H1 2017 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2017 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2017 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2017 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2017 83 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2017 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2017 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2017 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H1 2017 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2017 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2017 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2017 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2017 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2017 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2017 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma GmbH, H1 2017 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Humorigin Biotechnology Corp, H1 2017 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison China MediTech Ltd, H1 2017 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2017 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2017 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2017 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2017 93 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2017 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2017 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2017 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2017 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2017 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2017 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2017 97 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2017 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2017 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2017 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2017 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2017 100 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2017 100 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Corp, H1 2017 101 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H1 2017 101 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H1 2017 102 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2017 102 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mesoblast Ltd, H1 2017 103 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 103 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2017 104 Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H1 2017 104 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2017 105 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics Inc, H1 2017 106 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 107 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2017 107 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H1 2017 108 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H1 2017 108 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc, H1 2017 109 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals Inc, H1 2017 109 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Qurient Co Ltd, H1 2017 110 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H1 2017 110 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2017 111 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 111 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2017 112 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2017 112 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H1 2017 113 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2017 113 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H1 2017 114 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H1 2017 114 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H1 2017 115 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H1 2017 115 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017 116 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 116 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 117 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H1 2017 117 Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma Inc, H1 2017 118 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H1 2017 118 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H1 2017 119 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H1 2017 119 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H1 2017 120 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H1 2017 120 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc, H1 2017 121 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 768 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..1), H1 2017 769 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..2), H1 2017 770 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..3), H1 2017 771 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..4), H1 2017 772 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..5), H1 2017 773 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..6), H1 2017 774 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..7), H1 2017 775 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017 776 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017 (Contd..1), H1 2017 777
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
